Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 60

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 60
---
3) Amounts represent the acceleration of all unvested stock options and RSUs outstanding as of December 31, 2024. For unvested stock options, amounts are equal to the number of unvested stock options which are in-the-money as of December 31, 2024 multiplied by the difference between the $7.73 closing price of our common stock on December 31, 2024, as reported by Nasdaq, and the exercise price of the stock options. For unvested RSUs, amounts are equal to the number of unvested RSUs multiplied by the $7.73 closing price of our common stock on December 31, 2024, as reported by Nasdaq.

<div align='center'>42</div>

The following table summarizes the hypothetical payments that could have been incurred by the Company with respect to each of our NEOs, assuming that a qualifying termination or resignation under the applicable employment agreement had occurred without the potential effects involving a change in control:

| Name                 |     | Cash Severance(1) 
               ($) |     | Target Annual  
 Cash Incentive 
 ($)            |     |    COBRA 
 Premiums 
      ($) |     | Value of      
 Accelerated   
 Stock Options 
 and RSUs      
 ($)           |     |   Total 
     ($) |
| Curran Simpson       |     |           610,000 |     | —              |     |   21,053 |     | —             |     | 631,053 |
| Mitchell Chan        |     |           490,000 |     | —              |     |   27,709 |     | —             |     | 517,709 |
| Stephen Pakola, M.D. |     |           518,082 |     | —              |     |        — |     | —             |     | 518,082 |
| Olivier Danos, Ph.D. |     |           522,348 |     | —              |     |   27,709 |     | —             |     | 550,057 |
| Patrick J. Christmas |     |           500,868 |     | —              |     |   27,709 |     | —             |     | 528,577 |

(1) Amounts represent continued payment of 2024 base salary for 12 months for all NEOs. Mr. Mills did not receive any payment under his employment agreement in connection with his resignation as CEO